Acro Biomedical Co Stock Analysis
| ACBM Stock | USD 0.02 0.00 0.00% |
ACRO Biomedical holds a debt-to-equity ratio of 0.103. ACRO Biomedical's financial risk is the risk to ACRO Biomedical stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
ACRO Biomedical's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. ACRO Biomedical's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps ACRO Pink Sheet's retail investors understand whether an upcoming fall or rise in the market will negatively affect ACRO Biomedical's stakeholders.
For many companies, including ACRO Biomedical, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for ACRO Biomedical Co, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, ACRO Biomedical's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that ACRO Biomedical's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which ACRO Biomedical is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of ACRO Biomedical to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, ACRO Biomedical is said to be less leveraged. If creditors hold a majority of ACRO Biomedical's assets, the Company is said to be highly leveraged.
ACRO Biomedical Co is overvalued with Real Value of 0.0137 and Hype Value of 0.02. The main objective of ACRO Biomedical pink sheet analysis is to determine its intrinsic value, which is an estimate of what ACRO Biomedical Co is worth, separate from its market price. There are two main types of ACRO Biomedical's stock analysis: fundamental analysis and technical analysis.
The ACRO Biomedical pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
ACRO |
ACRO Pink Sheet Analysis Notes
About 50.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.2. ACRO Biomedical had not issued any dividends in recent years. The entity had 3:1 split on the 22nd of May 2017. Acro Biomedical Co., Ltd. engages in developing and marketing of nutritional products. Acro Biomedical Co., Ltd. was incorporated in 2014 and is based in Fishers, Indiana. Acro Biomedical operates under Biotechnology classification in the United States and is traded on OTC Exchange.The quote for ACRO Biomedical Co is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on ACRO Biomedical Co please contact PaoChi Chu at 317 286 6788 or go to https://acrobiomedicalco.com.ACRO Biomedical Investment Alerts
| ACRO Biomedical is way too risky over 90 days horizon | |
| ACRO Biomedical has some characteristics of a very speculative penny stock | |
| ACRO Biomedical appears to be risky and price may revert if volatility continues | |
| ACRO Biomedical has high likelihood to experience some financial distress in the next 2 years | |
| About 50.0% of the company shares are held by company insiders |
ACRO Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 209.55 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ACRO Biomedical's market, we take the total number of its shares issued and multiply it by ACRO Biomedical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
As of the 22nd of February, ACRO Biomedical shows the Coefficient Of Variation of 812.4, variance of 142934.45, and Mean Deviation of 91.66. ACRO Biomedical technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the entity's future prices. Please confirm ACRO Biomedical coefficient of variation, as well as the relationship between the total risk alpha and skewness to decide if ACRO Biomedical is priced adequately, providing market reflects its regular price of 0.0222 per share. As ACRO Biomedical appears to be a penny stock we also recommend to validate its information ratio numbers.ACRO Biomedical Price Movement Analysis
The output start index for this execution was nine with a total number of output elements of fifty-two. The Triangular Moving Average shows ACRO Biomedical double smoothed mean price over a specified number of previous prices (i.e., averaged twice).
ACRO Biomedical Outstanding Bonds
ACRO Biomedical issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ACRO Biomedical uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ACRO bonds can be classified according to their maturity, which is the date when ACRO Biomedical Co has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| ACRISURE FINANCE INC Corp BondUS00489LAF04 | View | |
| Acrisure LLC 144A Corp BondUS00489LAH69 | View |
ACRO Biomedical Predictive Daily Indicators
ACRO Biomedical intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ACRO Biomedical pink sheet daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 0.0222 | |||
| Day Typical Price | 0.0222 | |||
| Relative Strength Index | 100.0 |
ACRO Biomedical Forecast Models
ACRO Biomedical's time-series forecasting models are one of many ACRO Biomedical's pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ACRO Biomedical's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.ACRO Biomedical Debt to Cash Allocation
Many companies such as ACRO Biomedical, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
ACRO Biomedical Co currently holds 59.44 K in liabilities with Debt to Equity (D/E) ratio of 0.1, which may suggest the company is not taking enough advantage from borrowing. ACRO Biomedical has a current ratio of 7.55, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist ACRO Biomedical until it has trouble settling it off, either with new capital or with free cash flow. So, ACRO Biomedical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ACRO Biomedical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ACRO to invest in growth at high rates of return. When we think about ACRO Biomedical's use of debt, we should always consider it together with cash and equity.ACRO Biomedical Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the ACRO Biomedical's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of ACRO Biomedical, which in turn will lower the firm's financial flexibility.ACRO Biomedical Corporate Bonds Issued
About ACRO Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how ACRO Biomedical prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling ACRO shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as ACRO Biomedical. By using and applying ACRO Pink Sheet analysis, traders can create a robust methodology for identifying ACRO entry and exit points for their positions.
Acro Biomedical Co., Ltd. engages in developing and marketing of nutritional products. Acro Biomedical Co., Ltd. was incorporated in 2014 and is based in Fishers, Indiana. Acro Biomedical operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding ACRO Biomedical to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Risk-Return Analysis Now
Risk-Return AnalysisView associations between returns expected from investment and the risk you assume |
| All Next | Launch Module |
Other Information on Investing in ACRO Pink Sheet
ACRO Biomedical financial ratios help investors to determine whether ACRO Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ACRO with respect to the benefits of owning ACRO Biomedical security.